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 ABSTRACT 
 
Despite the high mortality rate of ovarian cancer, there are few selective 
biomarkers that detect its progression and none have become successful targets for 
therapy. A complex microenvironment that promotes angiogenesis, reduces immune 
responses and alters the integrity of the surrounding matrix is involved through the 
biology of ovarian cancer. Previous studies done by our lab and collaborators indicated 
that extracellular threonyl-tRNA synthetase (TARS) is a pro-angiogenic mediator of the 
ovarian tumor microenvironment, which is secreted in response to inflammatory signals, 
and actively promotes angiogenesis. In order to better understand the mechanisms 
underlying the angiogenic effects of TARS in ovarian cancer, it is essential to identify 
whether it directly affects ovarian tumor growth and invasion. Preliminary evidence 
indicated that TARS is secreted from ovarian cancer cells in response to TNF-α and 
TARS exhibits extracellular angiogenic activity. In previous studies, TARS was shown to 
significantly increase migration of HUVECs in a transwell assay to an extent that was 
similar to VEGF. 
The purpose of this project was to establish a role for TARS in tumor 
progression and its potential as a diagnostic marker using an animal model of ovarian 
cancer. The hypothesis tested is that TARS plays a key role in the angiogenic and 
invasive potential of ovarian cancer, and TARS inhibition will reduce the angiogenic 
effect of tumor cells which is reflected by measurement of intratumor microvessel density 
(MVD). The study tested the effect of BC194-mediated TARS inhibition on the 
development of ovarian tumors in ID8 mouse model. We found a positive correlation 
between TARS expression and ovarian cancer progression, and TARS inhibition with 
BC194 reduce the progression of ovarian cancer. These data suggest that TARS has an 
important role in the tumor microenvironment and that TARS inhibition should be further 
investigated as a therapy for ovarian and other angiogenic cancers. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Angiogenesis 
1.1.1 Angiogenic process and regulators of angiogenesis    
               A number of sequential events are involved in the formation of a new blood 
vessel.  For the ovary neovascularization, the cellular events are virtually identical no 
matter where the stimulus comes from. It could be either from periodic 
neovascularization of the normal ovarian follicle or from ovarian tumor cells (Brown, 
Blanchette et al. 2000). At a given time, endothelial cells exist in a near quiescent state 
with only 0.01% cells undergoing division prior to neovascularization. When a new 
vascular sprout forms, the turnover rate of endothelial cells increases up to 50-fold. In 
order to promote angiogenesis by unmasking pro-angiogenic molecules, remodeling of 
the extracellular matrix is required which is facilitated by secretion of matrix degrading 
enzymes (Baba, Mandai et al. 2004). 
     After the extracellular matrix is digested, motility-stimulating extracellular 
matrix fragments and growth factors are released to stimulate endothelial cells and create 
a framework for new vessels. Endothelial cell sprouts then proliferate and organize into 
tubular structures, form tight junctions and connect to the pre-existing vascular network. 
Angio-stimulatory molecules are secreted by non-endothelial cells and activated by 
surrounding stroma, which induce and maintain the angiogenic events. Physiological 
angiogenesis is basically a self-limited process and is regulated by endogenous angio-
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inhibitory molecules. This balance of angiogenesis is disturbed during cancer 
progression. 
 
   Tumor cells are able to secrete molecular modulators which initiate the 
angiogenic process. The newly formed blood vessels provide oxygen and nutrients for 
further tumor growth to overcome the diffusion-limited maximal size of approximately 2 
mm3 of a tumor mass. This ‘angiogenic switch’, the acquisition of the angio-stimulatory 
phenotype results from a local imbalance between angio-stimulatory and angio-inhibitory 
molecules. Malignant cells and/or the stroma may increase the production of angio-
stimulatory molecules (Glass, Quackenbush et al. 2015). Neovascularization increases 
blood flow, provides access for immune cells—which can also secrete angio-stimulatory 
molecules, and provides a means of egress for tumor cells, which finally become 
metastasis. 
         The balance of angio-stimulatory and angio-inhibitory molecules are kept by 
genetic regulation. A number of genes have been identified that regulate downstream 
molecules and pathways critical in angiogenesis, among which, P53 is a prominent one. 
P53 is a critical tumor-suppressor gene, been shown to participate in the control of gene 
transcription, DNA synthesis and repair, cell necrosis, tumor invasion and metastasis. 
 P53 is mutated in a majority of advanced stage ovarian cancers and is a potent 
prognosticator of poor clinical outcome (Glass, Quackenbush et al. 2015). Loss of wild-
type p53 promotes angiogenesis by upregulating vascular endothelial growth factor 
(VEGF), which is a potent mitogen for endothelial cells. P53 mediates upregulation of 
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hypoxia inducible factor-1 (HIF-1α), which induces the VEGF increase. HIF-1 is an 
oxygen-regulated transcriptional factor, composed of two subunits HIF-1α and HIF-1β. 
HIF-1 is able to bind the 5’ flanking regions of VEGF and activates VEGF transcription. 
Overall, loss of P53 enhances hypoxia-induced HIF-1α levels, induces HIF-1 dependent 
VEGF expression in tumor cells and promotes neovascularization of tumor xenografts 
(Glass, Quackenbush et al. 2015).   
       Angiogenesis is closely regulated by extracellular matrix (ECM) proteins 
through the integrin family of receptors. Integrins are divalent cation-dependent 
heterodimeric membrane glycoproteins comprised of non-covalently associated α and β 
subunits that promote cell attachment and migration on the surrounding extracellular 
matrix. 
           In vitro and in vivo data have implicated a number of endothelial cell integrins in 
the regulation of cell growth, survival and migration during angiogenesis. These integrins 
include the heterodimers α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, α9β1, αvβ3 and αvβ5. 
Despite the conflicting theories and evidences of several integrins in angiogenesis, 
including αv integrins and α2β1 integrin, some major roles for key integrins have been 
revealed.  The integrin αvβ3, a receptor for RGD-containing proteins such as vitronectin, 
fibronectin, fibrinogen and osteopontin (which are components of the ECM), was the first 
of the alpha v integrins to be characterized and shown to regulate angiogenesis (Brooks, 
Clark et al. 1994). This integrin is widely expressed on blood vessels in human tumor 
biopsies but not on vessels in normal human tissues. Its expression on endothelial cells is 
stimulated by angiogenic growth factors such as bFGF, TNFα, and IL-8 and it is 
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upregulated on endothelium in tumors, wounds and sites of inflammation (Brooks, Clark 
et al. 1994). Integrin αvβ3 antagonists induce endothelial cell apoptosis, increase the 
activity of the tumor suppressor p53 and increase levels of the cell cycle inhibitor p21 
WAF1/CIP1 and decrease levels of the anti-apoptotic protein BAX. It was also shown 
that integrin αvβ3 promotes angiogenesis and endothelial cell survival and angiogenesis 
is cancelled by integrin suppression. Ligation of endothelial αvβ3 integrin has also been 
shown to activate MAP kinase, focal adhesion kinase (FAK) and Src, among other 
kinases, resulting in cell proliferation, differentiation and migration (Eliceiri, Klemke et 
al. 1998). 
        Fibronectin is key extracellular matrix protein that is deposited by endothelial 
cell during normal and tumor angiogenesis. Short fibronectin peptide loops containing the 
sequence RGD interact with integrin such as α5β1, αvβ5 and αvβ3 (Plow, Haas et al. 
2000)  Fibronectin is essential for developmental angiogenesis as deletion of all 
fibronectin isoform is early embryonic lethal, with yolk sac and other mesodermal tissue 
defects. The most recent fibronectin-binding integrin to be found to play a role in 
angiogenesis is integrin α9β1. It is a receptor for a number of ECM proteins and cell 
surface receptors including tenascin-C, thrombospondin, osteopontin, IIICS fibronectin, 
VCAM and other ligands (Marcinkiewicz, Taooka et al. 2000). Fibronectin and several of 
its receptors clearly play central roles in promoting angiogenesis during development and 




1.1.2 Angiogenesis and ovarian cancer  
 The complexity of genetic and/or environmental initiating events and lack of 
clarity regarding the cells or tissues of origin is a major hindrance to better understand 
how the ovarian cancer (OvCa) initiation and progression. A series of events are involved 
in metastasis, such as direct extension or exfoliation of cells into the peritoneal cavity, 
survival of matrix-detached cells in ascites, and subsequent adhesion to the mesothelium 
lining covering abdominal organs to establish secondary lesion containing host stromal 
and inflammatory components (Baba, Mandai et al. 2004). It’s a remarkable challenge to 
develop experimental models to understand this unique mechanism of metastasis. Many 
approaches and knowledge used to study other solid tumors (lung, colon, and breast, for 
example) are not transferable to OvCa research given the fact that OvCa have distinct 
metastasis pattern and unique tumor microenvironment. 
              A correlation between clinical outcome and neovascularization of tumors, 
particularly in different OvCa subtypes, has been defined. Increased angiogenesis is a 
negative indicator of progression-free survival, overall survival, and predicts higher 
likelihood of metastasis in OvCa (He, Wang et al. 2015). Many factors such as tumor 
microvessel density and angiogenic cytokine expression as well as serum and urine levels 
of angio-stimulatory molecules have been used to study the role of angiogenesis as a 
prognosticator. Microvessel density is determined by counting the number of vessels 
which are stained immunohistochemically. Darai et al analyzed microvessel staining with 
CD31 (an endothelial marker, also known as PECAM) in 20 benign, 20 low malignant 
potential and 20 malignant ovarian tumors. Results found that microvessel counts in 
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ovarian cancers are higher than that of low malignant potential or benign tumors (Darai, 
Bringuier et al. 1998). A correlation between increased number of CD31-stained vessels 
and advanced stage and tumor grade was also observed. Orre et al found that microvessel 
counts are higher in mucinous than serous ovarian tumor subtypes, suggesting tumor 
vascularity may be associated with histological type (Orre, Lotfi-Miri et al. 1998). 
Hollingsworth et al. evaluated microvesssel density as a function of outcome in advanced 
stage ovarian carcinomas and found that increased microvessel density is associated with 
poor overall survival and shortened disease-free survival (Hollingsworth, Kohn et al. 
1995).  Angiogenesis has also been found to be a predictor of worse prognosis but not 
an independent variable in multivariate analysis. Abulafia et al used factor VIII staining 
to evaluate microvessel counts in primary and matched metastatic ovarian tumor samples. 
Microvessel counts in omental metastases, but not in primary ovarian tumors, correlated 
with pre-operative CA125 levels and patient survival (Abulafia, Triest et al. 1997).  An 
association between angiogenesis and poor prognosis early stage ovarian cancers was 
also observed by Paley et al. in a study where they assessed VEGF expression through in 
situ hybridization of 68 stage I and II cancers (Paley, Goff et al. 2000). 
 
 1.1.3 Targeted therapy against angiogenesis in ovarian cancer (OvCa) 
            Angiogenesis not only plays a fundamental role in normal ovarian physiology but 
is also critically important in the pathogenesis of OvCa. Angiogenesis also promotes 
tumor growth and progression through ascites formation and metastatic spread. VEGF, 
fibroblast growth factor (FGF), and their respective receptors are among the well-
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recognized promoters of angiogenesis. In addition, platelet-derived growth factor 
(PDGF), epidermal growth factor (EGF), angiopoietins, and hepatocyte growth factor are 
also known to involve in tumor angiogenesis (Paley 2002). OvCa cells express VEGF 
and VEGF receptor (VEGFR), and an association between VEGF expression and the 
development of malignant ascites and tumor progression has already established (Paley 
2002).  
              Tumor growth is significantly decreased when tumor vascularization is reduced, 
and without adequate vascularization, tumor cells undergo necrosis or apoptosis. Most 
notably among those factors, VEGF has emerged as a dominant pathway although 
mechanisms underlying angiogenesis in tumors are multi-factorial and still quite unclear. 
 Among the various treatments for patients with platinum-resistant OvCa, anti-
angiogenesis strategies are attractive. Bevacizumab (a monoclonal antibody to VEGF-α) 
was developed by Genentech, San Francisco, CA, USA and marketed as Avastin. In 
preclinical studies, bevacizumab used as maintenance therapy was shown to prolong 
survival by inhibiting or delaying disease recurrence in a murine OvCa model (Paley 
2002). Bevacizumab is now the most prominent anti-angiogenic therapy approved by the 
Food and Drug Administration (FDA) for patients with platinum-resistant recurrent 
ovarian cancer as well as other angiogenic cancers including colon, renal and lung 
cancers. Combination of bevacizumab and cytotoxic chemotherapy has resulted in 
statistically improved cancer-free survival and overall response rate. Bevacizumab is also 




1.1.4 Bevacizumab toxicity and adverse events  
               Although anti-VEGF therapy such as bevacizumab has been effective in OvCa, 
some severe complications such as gastrointestinal perforation, surgery and wound-
healing complications, and hemorrhage have been reported. Bevacizumab was 
discontinued in 8.4%-21% of patients across all tumor types because of adverse reactions 
(Paley 2002). A better understanding of the mechanisms of bevacizumab adverse effects 
and resistance still need further investigations. The exact mechanism of resistance for 
anti-angiogenesis therapies is still not clear, but several pro-angiogenic pathways within 
the tumor, such as Angiopoietin 1, Delta-like ligand 4/Notch, and microRNAa), immune 
response, induction of hypoxia may be involved (Paley 2002).  
 
1.2 Threonyl-tRNA synthetase 
1.2.1 Introduction to threonyl-tRNA synthetase 
               Threonyl-tRNA synthetase (TARS) is a class II ARS which catalyzes the 
attachment of threonine to its corresponding tRNA for use in translation. TARS has a 
molecular weight of 83kDa (human, monomer; 76 kDa E.coli). However, like other class 
II ARSs, the protein is typically found as a homodimer. There are four core domains 
conserved from prokaryotes to eukaryotes in the structure of TARS. Although TARS has 
been implied in angiogenesis and tumor cell growth, its role in extracellular signaling had 
not been studied previously before the Lounsbury and Francklyn labs’ work (Williams, 
Mirando et al. 2013). 
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 1.2.2 Non-canonical functions of threonyl-tRNA synthetase 
The canonical function of aminoacyl-tRNA synthetases (ARSs) is to attach amino 
acids to their cognate tRNAs a part of the protein synthesis machinery. Distinct non-
canonical functions of many ARSs in eukaryotes have been found, such as inflammatory 
response regulation, transcriptional regulation, gene silencing, etc. These secondary 
functions may explain the links between ARSs and diverse human diseases.  For 
example, correlations have been found between mutations in ARS and several nervous 
system-related disorders such as Charcot-Marie-Tooth disease, leukoencephalopathy, 
infantile encephalopathy, and a Type III Usher-like syndrome (Jordanova, Irobi et al. 
2006). The distinct mechanisms that connect ARS activity with the pathogenesis of these 
diseases and the other non-canonical activities are still not clear, indicating that ARSs are 
dynamic signaling molecules functioning beyond established roles. Some extracellular 
signaling functions of several class I ARSs have been shown in previous studies, which 
are stimulated by inflammatory response, and they display different roles in angiogenesis. 
Tyrosyl-rRNA synthetase (YARS) and tryptophanyl-tRNA synthetase (WARS) are 
secreted in response to the cytokines TNF-α and interferon, respectively. While a 
secreted cleavage fragment of YARS is found to be angiogenic, a splice variant of 
WARS is secreted and inhibits angiogenesis (Wakasugi and Schimmel 1999).   
 Threnonyl-tRNA synthetase (TARS) has not been previously associated with 
extracellular signaling, although there are findings implying that it may be involved in 
angiogenesis and tumor cell growth. The macrolide antibiotic borrelidin, a potent non-
competitive inhibitor of TARS, inhibits endothelial cell tube formation and reduces 
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metastasis in a mouse model of melanoma (Habibi, Ogloff et al. 2012). Among several 
derivatives of the original drug borrelidin, BC194 is less cytotoxic but retains the anti-
angiogenic properties of borrelidin, making it a good candidate to study the mechanism 
of TARS regulating angiogenesis (Moss, Carletti et al. 2006). 
           In a previous study done by the Lounsbury lab, TARS was found to be actively 
secreted and to exert angiogenic activity, including stimulation of endothelial cell 
migration. Based on the data from the study, a model of the mechanism of how TARS 
functions in angiogenesis was presented (Fig. 1) (Williams, Mirando et al. 2013). 
Although the form of TARS that is secreted and its putative receptors still remain 
unclear, that study implied TARS has a novel extracellular function, confirming TARS as 
the anti-angiogenic target of the borrelidin derivative BC194, and indicating secreted 
TARS probably has a role in angiogenesis and inflammation in cancer and autoimmune 
 
 
Figure. 1 Proposed model for TARS angiogenic activity. 




disease (Williams, Mirando et al. 2013). 
1.2.3 TARS and ovarian cancer 
Ovarian cancer is a highly angiogenic malignancy, and correlation between 
ovarian cancer progression and expression of angiogenic signaling molecules has already 
been established in many studies, two notables among these molecules are hypoxia-
inducible factor (HIF-1α) and vascular endothelial growth factor (VEGF). In a previous 
study done by Lounsbury lab, a relationship between TARS and human ovarian cancer 
was explored. It was found that levels of TARS in patient tumor and inflammatory cells 
correlate with angiogenesis and stage of disease (Wong, Wellman et al. 2003).  
              In a study done by the Lounsbury lab, TARS expression in human ovarian 
cancer specimens was measured. Experiments were design to detect only overexpressed 
TARS. A significant positive correlation between increasing disease stage and TARS 
staining intensity was revealed. Overexpressed TARS also co-localized with VEGF and 
was in proximity to areas of neovascularization indicated by the endothelial marker 
PECAM (CD31) (Wellman, Eckenstein et al. 2014). These data suggest there is a novel 
relationship between TARS expression and ovarian cancer, and indicates an association 
between TARS and its angiogenic roles in the ovarian cancer microenvironment. In the 
same study, it was also found that TARS was overexpressed in infiltrating leukocytes 
within ovarian tumors, TARS was secreted from ovarian cancer cells in response to cell 
stress, serum levels of TARS correlated with tumor levels of TARS, overexpression of 
TARS correlated with increased survival in late-stage disease. All of these evidences 
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1.3 Ovarian cancer 
 
1.3.1 Epidemiology and risk factors 
                Ovarian cancer is the sixth most common cancer in women (Vaughan, Coward 
et al. 2011). Among many subtypes, epithelial ovarian cancer is the most common, which 
results from malignant transformation of the ovarian surface epithelium. The disease is 
frequently presented in advanced stage and has a poor prognosis with present therapies. 
Incidence of epithelial ovarian cancer ranks high in Europe, the USA, and Israel, and 
relatively low in Japan and developing countries. The median age of patients is 60 years, 
and the average lifetime risk for women in developed countries is about one in 70. Family 
history of ovarian or breast cancer is found the most important risk factor, although a 
genetic predisposition (most notably breast cancer genes BRCA1/BRCA2 mutations) is 
present in only 10-15% of patients. For a woman with a BRCA1 mutation, the risk of 
epithelial ovarian cancer is 39-46%, and with a BRCA2 mutation, 12-20% (Christie and 
Oehler 2006). Lack of childbirth, early menarche, late menopause, and increasing age are 
also risk factors, whereas oral contraceptive use, pregnancy, tubal ligation, lactation 




1.3.2 Pathology of ovarian cancer 
          Epithelial ovarian cancers could either be serous (most common), mucinous, or 
endometrioid and less commonly clear cell, transitional, etc. Histologically, epithelial 
ovarian cancers are classified as grade 1, 2, 3 (Kaku, Watanabe et al. 2012). Embryonic 
origin of epithelial ovarian cancers come from the ovarian surface epithelium and the 
peritoneal and fallopian tube epithelia, although some ovarian cancers might originate 
from the distal tubes. Mucinous and endometrioid carcinomas usually have favorable 
prognoses, serous carcinomas less so, and undifferentiated carcinoma is the most 
aggressive subtype. Tumor grade is always a consistent prognosticator (Kaku, Watanabe 
et al. 2012). 
 
1.3.3 Causes and pathogenesis 
 The majority (approximately 90%) of ovarian tumors arise from the ovarian 
surface epithelium, which completely covers the surface of the ovary and is continuous 
with the abdominal mesothelium.  Gonadotropin receptors are expressed in epithelial 
cells, which interact with the ovarian stroma in the secretion of growth factors, cytokines, 
and steroids. The surface epithelial layer is disrupted after ovulation, and epithelial cells 
frequently grow into the stroma to form clefts or inclusion cysts. It was demonstrated in 
many studies that ovarian cancer originates from these clefts and inclusion cysts due to 
the interaction with the stromal environment full of hormones and growth factors. A 
number of subtypes of epithelial ovarian cancer have been identified histologically, with 
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approximately 80% of the classified as papillary serous epithelial (Kaku, Watanabe et al. 
2012). 
 For the different subtypes of epithelial ovarian cancer, despite the possession of 
unique molecular mutation and transcriptional abnormality, their morphology usually 
resembles the specialized epithelia of the reproductive tract that originate from the 
Mullerian ducts. Research suggests that epithelial ovarian cancer might all arise from one 
precursor cell of surface epithelium where homeotic genes (HOX genes) regulate 
embryonic pathways of differentiation. HOX genes are not usually expressed in ovarian 
surface epithelium.  However, introduction of expression of HOXA9, HOXA10, and 
HOXA11 to ovarian surface epithelium in tumorigenic mice is able to lead these cells to 
differentiate along different mullerian lineages, giving rise to tumors with characteristics 
of serous, endometrioid, and mucinous ovarian tumors, respectively (Kelly, Michael et al. 
2011). It was also found that HOXA7 controls the extent of differentiation and grade of 
ovarian tumors (Christie and Oehler 2006). Since HOX gene expression is regulated by 
sex steroids throughout the menstrual cycle, over-exposure of ovarian surface epithelium 
cells to these hormones in adult women might lead to abnormal HOX activation, leading 
to proliferation and genomic instability. 
 Genomic mutations have a critical role in the pathogenesis of many forms of 
epithelial ovarian cancer. It has been reported that high-prevalence somatic (non-
germline) mutations (>5%) only exist in a small number of genes in epithelial ovarian 
cancer(Christie and Oehler 2006). These mutations affect the pathogenesis in a similar 
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manner like HOX. These genes includeTP53, CTNNB1, and PTEN (all inactivated), and 
KRAS, Pik3CA, and AKT1 (all activated). 
 
1.3.4 Staging of ovarian cancer    
 In summary, there are four stages of the disease correspond to (I) ovarian, (II) 
pelvic, (III) peritoneal or coelomic, and (IV) metastasizing disease. Staging of epithelial 
ovarian cancers is shown in Table 1 (Mutch and Prat 2014).  From the primary tumor, 
propagation can occur throughout the abdominopelvic peritoneal compartment and to 
retroperitoneal pelvic, periaortic, suprarenal, mesenteric, and mesocolic lymph nodes. 
The most common extra-abdominal site of disease is the pleural space. Less frequently, 
distant metastases occur in the parenchyma of the liver, lungs, and other organs (Mutch 
and Prat 2014).  
 
Table 1: Ovarian cancer staging by International Federation of gynecology and 
obstetrics criteria 
Stage I: tumor restricted to ovary 
IA : limited to one ovary; capsules intact, no tumor on ovarian surface; no malignant cells 
in ascites or peritoneal washings 
IB:  limited to both ovaries; capsules intact, no tumor on ovarian surface; no malignant 
cells in ascites or peritoneal washings 
IC: tumor limited to one or both ovaries with capsule rupture or tumor on ovarian surface; 
malignant cells in ascites or peritoneal washings 
Stage II: tumor involves one or both ovaries with pelvic extensions 




IIB: extension to other pelvic tissues; no malignant cells in ascites or peritoneal washings 
IIC: pelvic extension with malignant cells in ascites or peritoneal wshings 
Stage III: tumor involves one or both ovaries with peritoneal metastasis outside the 
pelvis or retroperitoneal or inguinal node metastasis 
IIIA: microscopic peritoneal metastasis beyond pelvis 
IIIB: macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension 
IIIC: peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension or regional 
lymph node metastasis, or both. 
Stage IV: distant metastasis(excludes peritoneal metastasis) to liver parenchyma or 
other visceral organs or a malignant pleural effusion 
 
 
1.3. Markers for ovarian cancer 
        Identification of tumor markers and development of assays to measure them is 
an important goal in oncology. It is also important in differential diagnosis in order to 
establish appropriate management. It is difficult to distinguish diffuse peritoneal 
malignant mesothelioma from ovarian cancer, but differential diagnosis can be achieved 
by immune profile of the tumors with a systematic approach of both positive and negative 
mesothelioma markers (Hassan, Remaley et al. 2006). 
    Immunohistochemistry is used to achieve the definite diagnosis. Podoplanin, 
calretini, CK5/6, WT1, thrombomodulin, mesothelin, and D2-40 antibodies are used as 
positive markers of mesothelioma that are commonly expressed in mesotheliomas, but 
not in carcinomas, while Ber-EP4, MOC-31, TAG72, CA19-9, CD15(Leu-M1), 
monoclonal CEA and BG-antibodies are negative markers for mesothelioma that are 
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commonly expressed in adenocarcinomas(Taskin, Gumus et al. 2012). Mesothelin is 
highly sensitive for malignant mesothelioma, but its specificity is relatively low because 
some other tumors including ovarian cancer also exhibit mesothelin positivity. 
Nevertheless diffuse and strong membranous mesothelin expression serves as a strong 
indicator of particularly epitheliod mesothelioma rather than an ovarian carcinoma 
(Ordonez 2007).  
 Another distinguishing marker for ovarian cancer is estrogen receptor (ER) 
positivity. ER expression in malignant mesothelioma is a very rare phenomenon, and its 
positivity most probably indicates a serous carcinoma rather than a mesothelioma. 
Malignant mesotheliomas can be referred to gynecologic oncology clinics with primary 
ovarian masses or peritoneal carcinomatosis. This rate was calculated as 0.1% in one 
study (Taskin, Gumus et al. 2012). Clinical distinction of malignant mesothelioma from 
ovarian cancer or peritoneal adenocarcinoma is considered very difficult, but can be 
achieved by immune profile of the tumors. 
 
1.4. Modeling of ovarian cancer 
1.4.1 Cell lines and xenografts 
 Auersperg et al. first isolated human ovarian surface epithelial (OSE) cells in 
1984, which allowed the development of initial ovarian cancer models to evaluate the 
efficacy of the chemotherapy (Liu, Yang et al. 2004). These models typically involved 
the injection of human OvCa cells subcutaneously, intraperitoneally or orthotopically into 
immune deficient mice. A variety of responses of different levels occur, such as ascites 
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formation, primary tumor spread and tumor progression. All of these are helpful for the 
researcher to better understand the underlying mechanism of the disease. However, the 
limitations of this approach are evident with some drawbacks such as lack of the initial 
tumor-ovary interaction and the absence of an intact immune system in the host mice, 
while immune system has been implicated as a very important mediator of cancer 
progression and metastasis by many studies. 
 Although a number of ovarian cancer cell lines and primary tissues are currently 
available to mimic the molecular diversity, cellular heterogeneity, and histology seen in 
patient tumors, no uniform collection exists. Several human ovarian cancer cell lines can 
be used for xenograft studies in mice. Examples of the human cell lines which are 
suitable for development as murine xenografts are OVCAR-3 and SKOV3 (Peterson, 
Reed et al. 1992).  OVCAR-3 has been successfully grown in mice and develops as an 
intraperitoneal xenograft that retains many characteristics corresponding to its human 
tumor counterpart, similar to a serous ovarian cancer. The ovarian cancer cell line 
SKOV3 was collected from a patient in relapse after cisplatin and chlorambucil treatment 
and represents well differentiated serous adenocarcinoma cell lines, which is able to form 
xenograft tumors with a very similar histology to a human serous cancer. Several sublines 
of SKOV3 cells were made by passaging the cells in nude mice. In nude mice, the 
SKOV3 cells grow as disseminated disease, numerous (100-200) small nodules could be 
found on the surface of the peritoneum bowel mesentery, and diaphragm. Mouse 




 The development of mouse OvCa cell lines for use in syngeneic mouse models 
has the advantage of use in immunocompetent mouse models. For these models, mouse 
ovarian epithelial cells are collected from the mouse bursa and are passaged in culture 
until phenotypic changes occur. For example, cell contact inhibition could be lost, 
leading to changes in cell morphology. Neoplastic progression in the cell culture dish 
often includes the loss of tumor-suppressor proteins E-cadherin and connexin-43 (Roby, 
Taylor et al. 2000). 
 Ascites and metastatic tumors form 90 days after transformed OvCa cells are 
injected intraperitoneally into C57BL/6 mice, while solid tumor forms confining to the 
injection area if cells are injected subcutaneously. The significant disadvantage of the 
intraperitoneal model is that early events in metastasis cannot be fully appreciated, 
because the initial steps of tumor formation rely on the artificial dispersion of single cell 
suspensions of cancer cells in the peritoneal cavity, rather than progression of metastasis 
from an intact primary tumor tissue (Roby, Taylor et al. 2000). 
             The method of orthotopic ovarian xenografts is developed to better mimic the 
process of dissemination from the primary ovarian tumor relative to the intraperitoneal 
xenografts discussed above, and may be better for studying metastasis. However, 
significant anatomic differences exist between rodents and humans. The ovary of the 
rodents has a closed bursa enclosing it, while the ovary of the humans is exposed to the 
peritoneal cavity. 
             Several methods have been developed for orthotopic mouse models: injection 
under the ovarian bursa, intraperitoneal injection of minced human tumors, implantation 
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of human or murine tumor fragments adjacent to the ovary. Critical steps involved in 
ovarian cancer metastasis are invasion though the ovarian bursa, followed by peritoneal 
cavity spread and colonization and invasion of organs in the peritoneal cavity. When late 
passage cells from the mouse ovarian epithelial cancer cell line MOSEC were injected 
into athymic and syngeneic mice, tumor implants grew throughout the abdominal cavity, 
and produced hemorrhagic ascitic fluid. A highly malignant neoplasm resulted with both 
carcinomatuous and sarcomatous components. The ability and pattern that MOSEC form 
extensive tumors within the peritoneal cavity is very similar to stage III and IV ovarian 
cancer found in women (Roby, Taylor et al. 2000). Since in the syngeneic mice model, 
the immune systems are intact in mice, the ability of MOSEC to form extensive tumors 
within peritoneal cavity despite the immune response they dealt with, makes this model 
uniquely valuable for investigations of molecular and immune interactions in ovarian 
cancer development. 
    
  1.4.2 ID8 mouse model 
              In this project, the role of TARS in ovarian cancer were studied in a mouse 
model of ovarian cancer first described by Roby et al. (Roby, Taylor et al. 2000). This 
model was developed by propagating normal mouse ovarian surface epithelial cells in 
culture for multiple passages until they developed a transformed phenotype. 
Intraperitoneal or subcutaneous transplantation of the cells into standard C57BL/6 mice 
resulted in tumors and peritoneal ascites. As opposed to a xenograft model using human 
tumor lines in immunocompromised mice, the syngeneic nature of the ovarian model 
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allows the tumor-stromal interactions characteristic of genuine cancers to be more 
accurately reproduced. 
 1.4.3    ID8 cell gene status 
 The TP53 tumor suppressor gene has long been established as a critical regulator 
of cell proliferation and as a frequent target for mutation in cancer (Greenblatt, Bennett et 
al. 1994). The TCGA project identified TP53 mutations in 96% of ovarian cancers 
(Cancer Genome Atlas Research 2011). Whole-exome sequencing has been performed to 
assess the genomic landscape of the ID8 cell model to identify the functional mutations in 
genes characteristic of HGSC including Trp53 (the mouse p53 gene), however, no Trp53 
mutations were detected (Walton, Blagih et al. 2016).  Some mutations typically seen in 
clear cell (Pik3ca), low-grade serous (Braf), endometrioid (Ctnnb1), and mucinous 
(Kras) carcinomas were also notably not observed (Walton, Blagih et al. 2016).  
 Given the centrality of TP53 mutations in HGSC, p53 function was also 
assessed in ID8 cells, and a significant increase of p53 function was observed (Walton, 
Blagih et al. 2016). Following treatment with cisplatin and MDM2 inhibitor Nutlin-3, a 
marked increase in CDKN1A (p21) transcription was also detected, indicating that p53 
remains transcriptionally active. For intraperitoneal ID8 tumors, Sanger sequencing 
didn’t find Trp53 mutation in any tumor, including common hotspot mutations sites, and 
a wild –type pattern of p53 expression was confirmed with immunohistochemistry 
(Walton, Blagih et al. 2016). IHC examination of typical HGSC markers indicated that 
tumors were strongly and diffusely positive for WT1, but negative for PAX8. For Brca2, 
no functional abnormalities was identified in whole-exome sequencing. It was considered 
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that parental ID8 cells were able to form Rad51 foci in response to DNA DSB damage 
Together, these data suggest that parent ID8 is poorly representative of human HGSC 
(Walton, Blagih et al. 2016). 
        Roberts et al. compared the alterations of the actin cytoskeleton as well as 
expression of cellular adhesion proteins versus the number of passages to study the 
progression of ovarian carcinogenesis, showing that transformation from a premalignant 
to a highly malignant phenotype with downregulation of E-cadherin and connexin-43 
(Roberts, Mottillo et al. 2005). 
      In a study done by Greenaway et al.(Greenaway, Moorehead et al. 2008), ID8 
cells were injected into the ovarian bursal cavity of C57bL6 mice. The ID8 formed direct 
contact with the ovarian stroma, resulting in primary tumor formation, secondary 
peritoneal tumors, and extensive ascites fluid. The histological and gross pathological 
features resembled serous carcinoma. Increased expression of proliferative and survival 
markers, including phosphorylated Akt, proliferating cell nuclear antigen, and Bcl-2, 
were increased. VEGF levels were also increased in the serum and ascetic fluid. 
        Based on these findings, it seems that ID8, a widely used murine model of 
ovarian carcinoma, is a poor representative of HGSC, with a conspicuous absence of 
mutations in genes associated with human disease, and evidence of functional p53 
activity. It remains, however, a useful model due to its origin and ability to consistently 
form tumors that closely parallel the patterns seen in HGSC. 
          Genetically engineered mouse models of HGSC have been difficult to generate. 
Recently, two HGSC models were described: the Drapkin lab utilized the Pax8 promoter 
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to drive Cre-mediated recombination of Trp53 and Pten with Brca 1 or Brca2 in mouse 
fallopian tube secretory epithelium (Perets, Wyant et al. 2013). By morphology and IHC, 
the tumors resembled human HGSC, but no ascites was observed, and all Pten-/- mice 
developed endometrial lesions. In addition, no transplantable cell lines have been 
described from these mice. A second fallopian tube model has been described, with SV40 
large T antigen under the control of the OVGP-1 promoter. Again, STIC-like lesions with 
p53 signatures were described, as well as invasive tumors within the ovary. However, no 
peritoneal dissemination or ascites was seen, and, again, no lines that can be readily 
transplanted into nontransgenic mice have been described (Sherman-Baust, Kuhn et al. 
2014). Both of these models are undoubtedly of great importance. However, it was 
believed that a transplantable model, based on a single genetic background (C57BL/6), 
which recapitulates disseminated peritoneal disease with ascites and in which multiple 
genotypes can potentially be rapidly investigated in parallel, is an important adjunct to 
transgenic models. 
 
1.5 Quantification of Angiogenesis 
1.5.1 Microvessel density (MVD) 
      Many angiogenesis assays have been developed to assess the new blood vessel 
growth, including chick chorioallantoic membrane (CAM) assay, the corneal 
micropocket assay, dorsal skin fold chamber, and matrigel assay. Notably, tumor 
angiogenesis can be directly studied in solid tumor tissue specimens. The focus of this 
project was to determine the role of TARS activity in the vascularization of tumors in 
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developing ovarian tumors.  For this purpose, we used the most widely used method of 
quantifying new blood vessel growth:  the determination of intratumoral microvessel 
density (MVD) (Wild, Ramakrishnan et al. 2000).  
 The degree of angiogenesis of a tumor, as assessed by MVD, is a powerful 
candidate for prognosis and a predictive tool. The College of American Pathologists has 
investigated the prognostic and predictive factors in breast cancer and has ranked 
quantification of tumor angiogenesis by counting microvessels in immunostained tissue 
sections as category III evidence (Vermeulen, Gasparini et al. 2002). In a multivariate 
analysis, MVD was found to be the most accurate prognostic indicator in breast 
carcinoma for disease-free survival (He, Wang et al. 2015); better than size, grade, or 
estrogen receptor status. 
 
1.5.2 MVD Test Methods 
  Intra-tumor microvessels can be identified by immunostaining of endothelial 
cells. There are two kinds of human endothelial cell specific antibodies: the pan-
endothelial cells markers and antibodies that bind selectively to activated or proliferating 
endothelium. The pan-endothelial cell markers stain small and large vessels with equal 
intensity, and in both frozen and paraffin embedded samples with equal reactivity (Hasan, 
Byers et al. 2002). 
              The most commonly used antibodies include those against factor VIII related 
antigen, CD31/PECAM-1, and CD34. Factor VIII related antigen forms part of the von 
Willebrand factor (vWF) complex and plays a role in the coagulation process (Charpin, 
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Garcia et al. 1997). The platelet-endothelial cell adhesion molecule CD31/PECAM-1, is a 
transmembrane glycoprotein involved in cell adhesion, and CD34 is a surface 
glycoprotein of unknown function (Charpin, Garcia et al. 1997). 
                   Previous investigations on MVD in prostate cancer have demonstrated 
remarkable differences between vWF-MVD and CD34-MVD as well as CD31-MVD and 
CD34-MVD(Offersen, Borre et al. 2002). A quite heterogeneous staining pattern of 
endothelial cells for the three markers was observed in prostate cancer tissue: a 
significantly increased MVD was only reflected when the two endothelial markers, CD31 
and CD34, were used whereas vWF showed a significantly decreased number of 
microvessels in prostate cancer compared to benign BPH tissue. In prostate cancer 
specimens, benign tissue is displaced by invasive tissue, resulting in a decreased number 
of pre-existing mature microvesssels, which are visualized by vWF. Therefore, vWF is 
suitable marker for endothelial cells in benign tissue, but would seem to be an inferior 
marker for assessing newly developed microvessels in prostate cancer(Offersen, Borre et 
al. 2002).  
            The investigation on astrocytoma and oligodendroglioma are in accordance with 
our findings in prostate cancer: CD34 showed the highest sensitivity for vascular 
endothelial cells compared to CD31 and vWF.  Accordingly, the specificity of CD34 for 
endothelial cells is higher in malignant tumors than in more differentiated tumor entities. 
    The relative abilities of these antibodies to highlight the vasculature has aslo been 
examined in EOC. Detection of blood vesssels in tissue sections has recently been 
modified so that it is now possible to discriminate between newly formed immature 
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vessels and those that are more established and mature. Antibodies to α smooth muscle 
actin (α-SMA) appear to stain mature vessels because they attract a “coat” of 
periendothelial support cells—that is, pericytes and smooth muscle (α-SMA positive) 
cells. Antiangiogenic therapeutic procedures, such as the blockade of tumor cell VEGF 
production, result not only in a drop in the vessel count, but also a change in the ratio of 
immature/mature vessels because of the relative vulnerability of the immature vessels to 
this, and most other, forms of antiangiogenic treatment(Bamberger and Perrett 2002). 
        The problem of antigen specificity is highlighted by the detection of CD34 antigen 
on lymphatic vessels, perivascular stromal cells as well as other stromal elements while 
this is compounded by the absence of FVIII-RA on part of the capillary endothelium in 
tumor tissue. The disadvantages associated with staining for CD31 antigen include co-
staining of inflammatory cells, but these can be distinguished from endothelial cells on 
the basis of morphological differences, and frequent antigen loss due to fixatives that 
contain acetic acid. Microwave antigen retrieval effectively abolishes this problem but in 
prospective studies a careful selection of the most suitable tissue fixation procedure 
should still be performed. 
 Despite the fact that MVD is identified as an independent prognostic factor in 
solid tumors, several studies have questioned the finding. Besides the particular tumor 
biological factors that may obscure the relationship, other issues such as staining 
methodology have also been implicated. Lack of standardized immunohistochemical 
techniques because of the wide range of antibodies, antigen retrieval methods, 
designation of high and low vessel count groups (cut-off points), patient groups, vessel 
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quantification interpretation could all contribute to the discrepancy. The correct 
identification of the vascular hot spot within the tumor and observer experience are two 
of the most important factors. In one study that compared the effects of different 
methodologies on evaluation of tumor vascularity, specimens of breast, lung and oral 
carcinoma and normal breast tissue were investigated. A variety of factors such as 
pretreatment of sections (enzymatic digestion, heating), endothelial markers (von 
Willebrand factor or CD31 antibodies), method of quantification (highest microvascular 
density, average microvascular density and microvascular volume) and inter-observer 
variations were all found to alter the estimated vascularity (28). Notably, the pretreatment 
of sections before staining was found to be the variable that most significantly altered the 
calculated vascularity of tumors.       
 An international consensus on the methodology and criteria for evaluation of 
MVD was put forward to overcome some of the problems of discrepancy (Vermeulen, 
Gasparini et al. 2002). In this consensus, a standard method for MVD assessment was 
proposed to improve reproducibility and inter-observer compatibility with regard to the 
selection of representative tissue samples, tissue processing and immunostaining, 
selection of areas for microvessel calculation and vessel counting method within these 
areas. Given the subjective nature of vascular hot spot selection and individual 
microvessels identification, a training program for the inexperienced pathologist is also 
recommended. 
            
1.5.5 Microvessel density and metastasis         
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  Several studies have examined the connection between MVD and tumor 
progression and metastasis (30). A correlation between MVD, intravascular tumor cells 
and the pulmonary metastasis was reported in an animal tumor model more than 20 years 
ago, but was not confirmed concerning its clinical implications. It was shown in one 
research study that patients with a high vascular density had more frequent tumor cell 
shedding than patients with a low MVD. In another investigation concerning cutaneous 
melanoma, it was found that angiogenesis intensity in a human tumor is a good predictor 
for the probability of metastasis (Massi, Franchi et al. 2002). 
 The significance of tumor vascularity in clear cell renal cell carcinoma has been 
controversial, partly because the manual quantification of MVD within a small area of 
tumor was limited. In the study, MVD and vascular endothelial growth factor were 
assessed in both areas of tumor and normal kidney medulla within scanned images using 
imaging software. CD34 staining vessels were counted and intensity of VEGF staining 
measured. To improve the accuracies of manual quantification, a computerized image 
analysis was employed, which allowed assessment of large areas of tumor and 
surrounding normal tissue. The latter was used as an internal reference for normalization. 
Original values from tumor areas and adjusted values as tumor/normal ratios were 
obtained. It was reported there was no association between unadjusted MVD and clinical 
outcome. However, higher adjusted MVD was associated with shorter disease-free 
survival. The validity of manual counting has been questioned since its introduction, and 
computerized image analysis still needs improvement to satisfy the potential bias in 




1.6. Summary and hypothesis 
Ovarian cancer is a vicious malignancy with extraordinarily high mortality rate. 
There are few selective biomarkers that detect its progression and none have become 
successful targets for therapy. A complex microenvironment that promotes angiogenesis 
of the disease is deeply involved in the ovarian cancer progression and metastasis. 
TARS is a member of the ARS enzyme family with the canonical function to 
catalyze ATP-dependent formation of specific amnio-acyl tRNAs. A variety of non-
canonical functions of several ARSs were found, such as inflammatory regulation, cell 
migration modulation and angiogenesis.   
 Angiogenesis has been established a critical component of the tumor 
microenvironment, and anti-angiogenic therapies using the VEGF inhibitor bevacizumab 
for ovarian cancer have shown effectiveness. Although these therapies have shown a 
variety of extent of efficacies in patients with ovarian cancer, the treatment complications 
and lack of success in some patients lead to the exploration of new ovarian-specific 
angiogenic targets. 
In previous studies, several aspects of the non-canonical functions of TARS have 
been reported. TARS has been associated with autoimmune disorders including 
polymyositis and dermatomyositis through its identification as the target for the myositis 
autoantibody PL-7 (Howard, Dong et al. 2002). TARS was also detected in a genome-
wide RNAi screen for genes associated with protection from hypoxia. The studies done 
by the Lounsbury lab demonstrated that TARS was secreted from ovarian cancer cells in 
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response to TNF-α, exhibited extracellular angiogenic activity, and was able to induce 
endothelial cell migration. The studies also indicated that TARS was overexpressed in 
ovarian cancer, TARS was found to be expressed in colocalization with VEGF and its 
expression was positively correlated with ovarian cancer stage. In addition, analysis of 
TARS levels in patient serum samples showed a positive correlation with TARS tumor 
levels. 
All of these evidence and observations suggest several important questions to be 
resolved: is TARS protein expression characteristic of tumor development, and if so, at 
what stage of cancer development? Is such expression coincident with expression of 
angiogenic markers and/or vascularization? With our patient data as precedent, we 
examined these questions in the ID8 mouse model of ovarian cancer that has been well 
characterized and has the flexibility of altering TARS expression to determine its specific 





CHAPTER 2: METHODS 
2.1 Cell culture and reagents 
 The ID8-C3 cell line we used to generate ovarian tumors was originally 
generated by self-transformation of normal mouse ovarian epithelial cells and were 
generously supplied by Brent Berwin (Dartmouth College) (Roby, Taylor et al. 2000). 
ID8-C3 cell were cultured and propagated by serial passage in RPMI media 
supplemented with 10% fetal bovine serum and 0.1% gentamycin sulfate. After being 
injected into the mice intraperitoneally, these cells form tumors which mimic stage IV 
human ovarian cancer (Erickson, Conner et al. 2013). BC194 was obtained from Biotica 
(now Isomerase Therapeutics Ltd, Cambridge, UK). 
 
 2.2 Mouse modeling by injecting ID8-C3 ovarian cancer cells 
              C57BL/6 mice were used for ovarian cancer modeling and assessment of tumor 
formation. All the experiments performed in animals were in compliance with IACUC 
protocols (IACUC #13-044).  Mice were housed 3 per cage in the standard mice 
plexiglass cages and maintained on a 12 h light: 12 h dark cycle (lights on at 7.00 a.m) in 
a temperature-controlled room (22±2°C) with food and water ad libitum at all times.  
 The injection protocol followed the previous research (Roby, Taylor et al. 2000). 
For injections, ID8-C3 cell were grown in culture, collected by trypsinization and 
centrifugation, and then resuspended in PBS.  3×106 cells were injected intraperitoneally 
into normal six-week-old female C57BL/6 mice (Mirando, Abdi et al. 2016). 
Intraperitoneal tumor formation was monitored by the accumulation of ascites fluid 
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(Roby, Taylor et al. 2000). For specific experiments, three weeks after the cell injection, 
mice were administered vehicle (DMSO) or the TARS inhibitor BC194 (2 mg/kg 
intraperitoneally 3 times per week for 3 weeks). After injections, the mice were evaluated 
3 times every week for the development of ascites by detecting abdominal swelling. The 
mice were euthanized 6-8 weeks after the initial injection. At the time of death, ascites 
fluid was collected from the peritoneal cavity using 10 cc syringe fitted with a 22 g 
needle. Blood was also collected in heparin solution, and was serum obtained by 
centrifugation. The abdominal cavity was opened with a single midline incision, tumors 
in the abdominal cavity were photographed and tumor locations and sizes were noted for 
staging. As described in (Roby, Taylor et al. 2000), amount of tumor on tissues and 
organs was scored on a 0, +, ++, +++ scale: see Table 2. Tumors and surrounding tissues 
were collected from multiple sites, fixed in 4% paraformaldehyde and embedded in 
paraffin for future analysis by immunofluorescence and to quantify MVD.    
 
 
Table 2:  Description of Tumor scoring  
Tumor Score Description of tumors  
0 No tumor evident by gross examination 
+ Tumors grossly evident on one organ or tissue 
++ Moderate tumor formation on more than one organ or tissue 






2.3 Immunofluorescence analysis           
 Serial sections (5μm) from paraffin-embedded specimens were cut and 
transferred to positive ion-charged slides. The slides were then deparaffinized and 
rehydrated by use of xylene, 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, 
followed by a thorough wash with deionized water. Slides were treated with antigen 
retrieval buffer Dako S1699 for 20 minutes at 95-98°C. After at least 20 minutes cooling, 
slides were blocked with 3% BSA/0.2% TX-100/PBS for one hour at room temperature, 
followed by incubation with primary antibodies as described in Table 3. Slides were 
Table 3: Primary antibodies used for Immunofluorescence 
Primary antibody  Product # species dilution 
anti-ThrRS GTX116359 Rabbit 1:400 
anti-SMactin Sigma A2547 Mouse 1:200 
anti-CD3 Biocare CP215A Rabbit 1:100 
anti-PECAM-1 SC-1506 Goat 1:100 
 
Table 4: Secondary antibodies used for Immunofluorescence 
Secondary antibody dilution 
Alexa 488 donkey anti-ms IgG 1:500 
Alexa 594 donkey anti-rab IgG 1:500 




incubated in a humidified box at 4 °C for 16–24 h and then washed several times in a 
Coplin jar with PBS. All antibodies were titrated to optimize signal to noise ratio.  
Secondary antibodies used were Invitrogen’s Alexa Fluor 488 donkey anti-goat IgG and 
Alexa 594 donkey anti-rabbit IgG in 3% BSA/0.1% TX-100/PBS (see Table 4). Each 
section was counterstained by using a premixed solution of 4, 6-diamidino-2-
phenylindole (DAPI) (10μg/ml). After staining with secondary antibodies, the slides were 
washed with PBS and mounted with coverslips using AquaPolyMount. Images were 
collected using a fluorescence microscope using either a 10× or 20× objective. Analysis 
of Intratumor microvascular area (IMA) was conducted with MetaMorphTM (Molecular 
Devices) software as described below. 
 
2.4   Immunohistochemistry 
 Formalin-fixed paraffin-embedded sections (thickness 5 μm) underwent 
deparaffinization and antigen retrieval as in the immunofluorescence protocol. 
Endogenous peroxidases were then blocked by submerging the slides in 2.5% hydrogen 
peroxide/methanol buffer for 15 minutes. Nonspecific background was minimized using 
0.3% bovine serum albumin in 0.1 mol/L Tris-buffered saline for 1 hour. Primary 
antibodies used were as described in Table 5 and sections with primary antibodies were 
incubated 16-24 h at 4°C in humidity box. Secondary antibodies described in Table 6 
were applied for 30 minutes at room temperature. 
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 The sections were then processed with an avidin-biotin-peroxidase complex 
(ImmPRESS; Vector Laboratories, Burlingame, CA), revealed in the presence of 3,3’-






Table 5: Primary antibodies used for Immunohistochemistry 
Primary antibody Product Species dilution 
Anti-ThrRS GTX116359  Rabbit 1:200 
Anti-CD31 Biocare CP215A  Rabbit 1:100 
Anti-F4/80 SC-25830 Mouse 1:100 
Anti-SMactin Sigma 1A4 Mouse 1:500 
Anti-PECAM-1 SC-1506  Goat 1:100 
 
Table 6: Secondary antibodies used for Immunohistochemistry 
Secondary antibody spec 
Anti-rabbit IgG  DAKO Polymer-HRP goat 






2.5 Intratumor quantification of MVD 
    MetaMorph offline software was used for computerized quantification of 
immunostained vascular structures (Chantrain, DeClerck et al. 2003).  PECAM-1-postive 
pixels were selectively detected and uniformly displayed with green pixel overlay using 
the threshold function. With the command <Threshold Image> from the <Measure> 
menu, regions with heavily PECAM-1 staining were added, regions of counter-staining 
and background without PECAM-1 were deleted respectively and successively. These 
two steps were repeated until all the PECAM-1-positive pixels were selectively threshold. 
The threshold area corresponding to the PECAM-1 represented the intratumor 
microvascular area (IMA) and was measured with the <Region Measurement> function. 
For the whole section images, the PECAM-1(IMA) was selectively measured on the 
tumor tissue delineated by using the <Trace Region> command of MetaMorph. 
Neighboring connective tissue and necrotic areas were excluded from the selection. 
Similar procedures were done to TARS staining area (tumor area), the MVD was 
expressed as a ratio of PECAM-1-positive thresholded pixels to TARS positive staining 
area. 
 
2.6 Statistical Analysis 
               All experiments were repeated at least 3 times with specific n-values reported 
within the Figure Legends. Data are presented as mean ± SEM, and P < 0.05 was 





                                                    CHAPTER 3: RESULTS  
3.1 Mouse Model of Ovarian Cancer 
 To assess the relationship between TARS activity and ovarian cancer 
angiogenesis, a mouse model of ovarian cancer was established, a regimen of TARS 
inhibitor vs. vehicle was administered, and the microvessel density (MVD) of resulting 
ovarian tumors was detected by immunostaining and quantified by MetaMorph offline 
software. Comparisons were made to test the hypothesis that TARS activity promotes 
progression and angiogenesis of ovarian cancer.  
 Normal female C57BL/6 mice were used for assessment of the tumor formation. 
ID8-C3 cells were injected intraperitoneally (3×106 cells in 0.2 ml PBS). Animals were 
evaluated weekly for tumor growth and/or ascites accumulation. Intraperitoneal tumor 
formation was monitored by the accumulation of ascites fluid. Animals were euthanized 
approximately 10-24 days after the development of visible ascites, detected by abdominal 
swelling (Fig. 2). Immediately after euthanization, ascites fluid was collected from the 
peritoneal cavity. The peritoneal and thoracic cavities were opened. Solid tumors of 
varying size developed in the abdomen of mice by 5-6 weeks post-injection. The overall 
tumor take-rate was 100%. Tumor location and sizes were noted and amount of tumor on 
11 tissues and organs was scored on a 0, +, ++, +++ scale: 0, no tumor evident by gross 
examination; +, tumors grossly evident on one organ or tissue, ++, moderate tumor 
formation on more than one organ or tissue; +++, extensive tumor formation on several 














Figure 2. Development of ascites in syngeneic, orthotopic ID8-3 tumor model. C57BL/6 mice 
were injected with 3×106 ID8-3 ovarian cancer cells. Shown is the development of visible 






A. Mouse Anatomy B. Abdominal Wall tumors
C. Stomach tumors D. Mesenteric tumors
 
 
Figure 3. Generation of epithelial ovarian cancer in a syngeneic, orthotopic 
model.  (A) Drawing of mouse anatomy ; (B,C,D) Gross anatomical pathology of 
representative mice, 5 weeks after ID8-3 intraperitoneal injection (B) Abdominal 
wall tumors, (C) Stomach tumors, and (D) Mesenteric tumors. These animals 




3.1.1 ID8-C3 tumors express TARS and are angiogenic 
 Previous data from the Lounsbury lab demonstrated an increase in TARS 
staining in human ovarian cancer patient samples that correlated with progression of 
disease (Wellman, Eckenstein et al. 2014). To determine if the ID8-C3 model of ovarian 
cancer also overexpressed TARS, paraffin-embedded tumor samples were sectioned and 
stained to detect TARS using immunohistochemistry. As shown in Fig. 4, the ID8-C3 
tumors exhibited heavy staining for TARS, suggesting that these tumors also overexpress 
TARS, thus serving as a good model for studying the role of TARS and tumor 
angiogenesis. 
 
 Ovarian tumors in humans are known to induce angiogenesis, and anti-
angiogenic therapy is offered to patients that have been resistant to standard therapies 
A. No Primary B. TARS
 
 
Figure 4.  ID8-C3 ovarian tumors express high levels of TARS. Tumors were 
dissected from mice and then fixed, embedded, and sectioned. Sections were 
incubated with either normal mouse IgG (No Primary) or anti-TARS antibody and 
visualized by immunohistochemistry as described in the Methods. 
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(see Chapter 1). To show the angiogenic nature of the ID8-C3 ovarian cancer model, the 
angiogenic marker, α-smooth muscle actin (α-SMA), was detected in tumors by 
immunohistochemistry. The tumors exhibited angiogenesis (Fig. 5), however it was 
difficult to quantify the microvessel density using this technique, thus assessment of 
angiogenesis and quantification in later experiments was performed using 
immunofluorescence. 
3.1.2 Summary of Ovarian Cancer Progression in the ID-8 Model 
 Mice receiving ID8-C3 cell injection into the abdomen displayed abdominal 
distension at approximately 4-5 weeks post-injection (Fig. 2). This abdominal distension 
was a result of the hemorrhagic ascites formation that was accompanied by peritoneal 
carcinomatosis.  Tumor lesions were located throughout the peritoneum and were 
α-SMA
  
Figure 5. ID8-C3 tumors are angiogenic. Tumors attached to the abdominal wall 
were fixed and stained by immunohistochemistry to detect the blood vessel marker, α-
smooth muscle actin (α-SMA). The inset shows a magnified section of the maturing 
blood vessel within the tumor tissue with attached abdominal muscle tissue.  
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observed on all visceral and peritoneal surfaces (Fig. 3). Gross and histological 
examination of the thoracic cavity did not show any metastasis to the lungs or liver, 
however one animal had a visible tumor on the kidney. Tumors displayed both a high 
level of TARS expression and were angiogenic (Figs. 4,5), suggesting that this model is 
appropriate for studying the effects of TARS inhibition on tumor progression and 
angiogenesis. 
3.2 TARS inhibition with BC194 inhibits tumor progression 
 To determine a role for TARS in the progression of the ID8-C3 ovarian cancer 
model, mice were injected with ID8-C3 cells as in the baseline modeling, and after 3 
weeks of tumor establishment, animals were weighed and injected with either vehicle or 
the TARS inhibitor BC194, three times per week for 3 weeks. There are 6 mice each for 
control and treatment group. The animal weights did not significantly differ between 
groups, however there was a significant reduction in the tumor progression score for the 
animals treated with BC194 (Fig. 6).  
  To compare the status of attaching and invading peritoneal organ sites, we 
examined tumor metastases on omentum, diaphragm, PW, liver, kidney, intestine and 
adipose tissue under a dissecting microscope (Fig. 7). We found that the omentum was 
the favored tissue for invasion of ID8 cells. The attachment and/or invasion of tumor 
cells to omentum were not significantly different between control and treatment mice, 




























Figure 6.  ID8-C3 Tumor Score is reduced by BC194 treatment. (A) The growth 
rate (slope) of animal weights is not different between the two groups. The curves 
were compared by linear regression analysis and there were 3 mice per group. (B) 
Tumor location and sizes were noted and amount of tumor on 11 tissues and organs 
was scored on a 0, +, ++, +++ scale: 0, no tumor evident by gross examination; +, 
tumors grossly evident on one organ or tissue; ++, moderate tumor formation on more 
than one organ or tissue; +++, extensive tumor formation on several organs or tissues. 
Significant difference of tumor progression score was observed between control and 



















Figure 7. Inhibition of TARS with BC194 reduces the tumor burden of ID8-C3 
ovarian cancer. Shown are representative images of mice after 6 weeks of tumor cell 
growth with injections of vehicle or BC194 beginning at 3 weeks. (A, B) represent 
abdominal cavity; (C, D) illustrate omental invasion. 
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3.3 Inhibition of TARS with BC194 inhibits angiogenesis  
      Immunofluorescent staining for the endothelial marker CD31 revealed 
distributed microvessels in the ID8 tumors with different degrees of vascular branching 
and irregularities. We examined whether the microvessel density could be quantified with 
the whole section scanning method. Using MetaMorph, we calculated the MVD on 
images of an entire ovarian tumor section generated by slide scanning and on a montage 
of serial microscopic field pictures. MetaMorph offline software was used for 
computerized quantification of immunostained vascular structures. PECAM-1 and TARS 
positive pixels were selectively detected and MVD was expressed as a ratio of PECAM-
positive thresholded pixels to TARS. 
 In tumor sections with immunofluorescent staining, blood vessels and immune 
cells were observed. Fig 8A shows the endothelial vessel cells stained by CD31 (green), 
Fig 8B shows the combination of the blood vessel (green) and CD3+ T-cells (red), Fig 
8C is a merged image of the tumor blood vessel (green) and nuclei (blue). The staining of 
endothelial cells was intensive, specific and easy to visualize for CD31. Tumors were 
frequently heterogeneous in their microvessel density, but the areas of highest 
neovascularization were found by scanning the tumor sections at low power (i.e., 
10×objective lens and 10×ocular lens). 
 With the Metamorph system, we are able to generate the CD31 microvessel area 
(MVA) in tumor section images. Shown in Fig 9 A is the tumor mask created by TARS 
immunofluorescence and Fig 9B is the Metamorph image of CD31 staining. With the 
tumor mask and CD31 staining images, we are able to measure the microvessel density 
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(CD31 area/area of entire tissue spot). The MVD values were compared between BC194 
treatment group and control group. The MVD (represented by tumor mask area) ranged 
from 0.181 to 0.469 in control, and from 0.008 to 0.128 in the BC194 treated. The 
treatment of BC194 reduced the MVD from an average of 0.331 to 0.106 and this 
difference was significant (p<0.005) (Table 7). These data together suggest that the effect 
of BC194 on the inhibition of tumor angiogenesis is related to the attenuation of ovarian 









Figure 8. Representative staining of the blood vessel and immune cell markers in 
tumor sections.  Immunofluorescent staining of mouse ovarian cancer tissues. The 
images shown are ×40 magnification immunofluorescence images of tissue tumor 
staining. (A) Endothelial vessel cells obtained from the CD31 staining (green) (B), 
Combined image of the tumor blood vessel (green) and CD3+ T-cells (red) (C) 
















Figure 9. Representative tumor section showing the mask to generate the CD31 
microvessel area (MVA) in Metamorph. A, TARS immunofluorescence from which 
the Metamorph algorithms create a tumor mask. B, The Metamorph image of CD31 
staining generated by the mask. Microvessel density was defined as CD31 





Table 7. Relationship between BC194 treatment and microvessel density (MVD) 
determined by an anti-CD31 monoclonal antibody (CD31-TMA) in mouse ovarian 
tumors (n=7 for each group; p<0.005 by Student’s t-test). 
 























Average (n=7) 0.331 0.106 0.0026 





CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
              Angiogenesis is critical for tumor growth. It was shown by many research 
groups that tumor neovascularity is associated with poor patient survival in a series of 
cancers. An increased MVD is positively correlated with early progression in a number of 
tumors. Such an association is likely due to increased supply of oxygen and nutrients by 
increased neovascularization in tumors. A high MVD is also more frequently observed in 
more actively proliferating tumors. Higher tumor vascularization also leads to an 
increased possibility for malignant cell infiltration and metastatic dissemination. 
       Several methods have been developed to measure the degree of angiogenesis, 
including determination of MVA, MVD. To date, MVD has been most extensively used 
to evaluate prognosis for various tumor types, but the results is inconsistent. The 
prognostic role of MVD is still unclear in ovarian cancer, one of the most vascular solid 
tumors. It was reported that increased MVD was associate with increasing nuclear grade, 
proliferative activity and frequency of metastasis, and higher microvessel count was 
observed in patients with metastasis than those disease free patients. In contrast, patients 
with a high MVD tumors were found to have a high 5-year survival rate.  The existent of 
large-diameter may help to explain these conflicting findings, because large-diameter 
vascular channel lowers MVD and offsets the significance of MVD in evaluating the 
aggressiveness of the tumors. 
               Various models have been developed to study ovarian epithelial surface cells. 
In rodent models, human cancer cell have been used as xenografts in immunodeficient 
mice. One notable problem of these models is that there is no tumor and stromal cells 
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interactions because the immune system of the models are absent. It is especially 
concerned in ovarian cancer model because ovarian cancer is a disease where immune 
response is deeply involved in the carcinogenesis, progression and metastasis. 
           In this study we investigated the role of TARS in angiogenesis of ovarian tumors 
using a mouse model of ovarian cancer first described by Roby et al. The ID8 model was 
developed by propagating normal mouse ovarian epithelial cells until they developed a 
transformed phenotype. Transplantation of the cells by IP injection into standard 
C57BL/6 mice results in tumors and peritoneal ascites. As opposed to a xenograft model 
using human tumor lines in immunocompromised mice, the syngeneic nature of the 
ovarian models allows the tumor-stromal interaction characteristic of genuine cancers to 
be more accurately reproduced.  
 Previous data from the Lounsbury lab demonstrated an increase in TARS 
staining in human ovarian cancer patient samples that correlated with progression of 
disease (Wellman, Eckenstein et al. 2014). In order to assess the relationship between 
TARS activity and ovarian cancer angiogenesis and progression, we used the ID8 model 
and the borrelidin analog BC194 to specifically inhibit TARS.  In this study, we observed 
that ID8 tumors exhibit heavy staining for TARS, suggesting the overexpression of 
TARS in tumors, thus serving as a good model for studying the role of TARS and tumor 
angiogenesis. Despite the widely used microvessel number counting from 
immunohistochemical staining (Hasan, Byers et al. 2002) , we observed that it was 
difficult to quantify the microvessel density of the ID8 tumors using this technique, so we 
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chose to use the immunofluorescence method to assess and quantify the microvessel 
density in experiments.  
 To determine whether inhibiting excess TARS function could reduce tumor 
progression, we treated mice with BC194, a TARS inhibitor. It was observed that in 
animals treated with BC194, the tumor progression score was significantly reduced 
suggesting that blocking TARS reduces ovarian tumor progression. Notably, the BC194 
treatment did not result in any observed pathology or change in animal behavior. To 
assess whether the drop in tumor progression was related to TARS function in 
angiogenesis, we measured microvascular density in the tumors using CD31 
immunofluorescence and computer image analysis. The data revealed that BC194 
significantly reduces the MVD. All the above findings suggest that TARS may have a 
role in the angiogenesis in mouse ovarian cancer, and we propose that the reduced 
angiogenesis prevents the progression of ovarian cancer.  
 Although we successfully established the mouse model for the assessment of 
role of TARS, and developed the Metamorph system method to evaluate the microvessel 
density rather than manually counting the number of blood vessel, there are still some 
limitations in this study. First, more subject numbers are needed in order to achieve more 
rigorous data. Secondly, the staining methods for TARS and microvessels also need 
improvements. Third, the use of TARS as a possible diagnostic measure was not 
evaluated. These weaknesses can all be addressed in the future experiments. 
 Assessment of microvessel density is mostly done by manual counting of 
vascular profiles in tissue sections in which blood vessels are stained using antibodies 
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directed against endothelial cells (Weidner 1995). The most widely used protocol was 
described by Weidner et al., in which vessels are counted in the so-called ‘angiogenic hot 
spot’ (Weidner 1995).  The hot spot is defined as the area of a tumor with the highest 
degree of vascularization. The hot spot is performed at low magnification and 
microvessel density measurements are performed at higher magnification. The outcome 
of the measurements is expressed either as the number of microvessels in hot spot or as 
the mean microvessel density assessed over a small number of highly vascularized areas 
of the tumor (van der Laak, Westphal et al. 1998). The selection of the hot spot is most 
critical in this protocol, because it has been shown to be subject to observer variation. 
The inter-observer variation limits the use of the hot spot procedure to construct reliable 
criteria for the prognostics of the metastasis of tumor. The objective selection criteria for 
both the hot spot and the microvessels are critically needed in order to achieve a reliable 
and reproducible hot-spot method. 
   Quantification of stained vessels can be achieved by measuring highest 
microvascular density (h-MVD), the average microvessel density (a-MVD) or the 
microvascular volume (MVV).  Under low magnification (100× magnification), the area 
of highest microvascular density (the vascular hot spot) is located by scanning the 
section.  In practice, three different areas are counted in order to localize the highest 
density. Three different fields are counted in each of these areas at 200× magnification, 
and the highest value taken as the h-MVD, expressed as vessels per mm2.  The 
measurement method for a-MVD is same as for h-MVD, and the mean of the vascular 
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counts obtained in at least 10-15 random fields is calculated for each tissue section. 
Results for a-MVD are expressed as mean ± standard deviation (vessels per mm2).  
 The MVV is estimated by point counting using an eyepiece grid, which contains 
100 points. Vessels that coincide with the points are counted in 15 fields selected 
randomly across each section (a total of 1500 points) and yields results expressed as 
percentage volume.  Manual counting of microvessels is very subjective and may lead to 
huge interobserver variability, which may explain conflicting results (Vermeulen, 
Gasparini et al. 2002).  A research was done to assess the efficacy and consistence 
between manually counting the number of microvessels in a subjectively selected hot 
spot and the interactive and automated image processing methods in the same complete 
tumor sections. 
              The Chalkley method is similar to that used to determine the MVV. 
First, the areas that appear to have the maximum number of discrete microvessels is 
identified at low magnification. An eyepiece grid containing 25 randomly positioned dots 
is rotated at higher magnifications to make the maximum numbers of points are on or 
within the vessels of the vascular hot spot. Instead of counting the individual 
microvessels, the overlying dots are counted. In cohort of patients with breast carcinoma, 
a significant correlation was found between MVD assessment by the Weidner method 
and Chalkley point counting. A significant reduction in OS was observed between 
patients stratified by Chalkley count in both univariate and multivariate analysis. The 
Chalkley score was also found the most significant independent predictor of outcome in 
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another study in patients with node-positive breast carcinoma (Vermeulen, Gasparini et 
al. 2002). 
  The first problem arising with these quantification methods is the selection of a 
representative tumor block.  In one research, MVD in in-situ growth regions is found 
approximately half of that seen in invasive regions in colorectal adenocarcinoma, 
suggesting that multiple blocks should be assessed. The de Jong et al group found that 
when more than one tissue block was analyzed compared to only counts within sections 
of one block were examined, a higher average coefficient of variation was achieved, 
indicating that a comprehensive inspection of available tumor material is needed to 
identify the relevant hot spots. 
 Another factor that influences the identification of the vascular hot spot is the 
training and experience of the investigator. In a research done by Barbareschi et al, MVD 
in 91 node negative invasive breast carcinomas measured by two pathologist of different 
experience was compared, only the counts of the experienced pathologist were 
significantly associated with relapse-free survival (Bevilacqua, Barbareschi et al. 1995).  
Similar results were noted in another series of node negative breast cancer patients.  Once 
the vascular hot spot is identified, vessel counting appears to be less variable than the 
process of hot spot selection. 
  There is an automated counting technique (CIAS) that improves reproducibility 
and reduces inter-observer variability and has been proposed as a more objective method 
of assessing MVD (Charpin, Garcia et al. 1997).  In a series of 91 node-negative invasive 
ductal carcinomas of the breast, both the number of CD31 positive microvessels 
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measured by an experienced observer and the microvessel area (MVA) determined by 
CIAS were independently associated with recurrence-free survival (Charpin, Garcia et al. 
1997).   The main advantage of CIAS is the additional morphometric parameters that can 
be detected the number of vessels with a certain dimension range, the vessel luminal area, 
vessel luminal perimeter and the number of immunostained areas per microscopic field. 
MVD can be measured more objectively without the intervention of an investigator. The 
apparent disadvantage of CIAS is the time consuming nature of the method and its higher 
cost. These systems are not fully automated yet and require a high degree of operator 
interaction. The vascular hot spot is still identified manually before automated counting 
as the heterogeneity of microvessel morphology and immunostaining intensity 
particularly hampers a fully automated analysis of tumor MVD. 
 Taking these studies into consideration, our angiogenesis quantification method 
had strengths with respect to its computer analysis rather than counting vessels by eye, 
however using more samples and developing a CIAS-like method for unbiased selection 
of area for quantification would improve the reliability of results. Future directions would 
also include a study of overexpressed TARS in the implanted ID8 cells where we would 
expect the resulting tumors have enhanced angiogenesis. A current analysis is being done 
in the Lounsbury lab of subcutaneous ID-8 tumors which will be a better model to 
quantify primary tumor size.   
 Another important parameter that remains to be studied is the use of TARS 
levels as a diagnostic in ovarian cancer. We found that TARS is overexpressed in the ID8 
tumors, and we collected serum and ascites fluid from the animals used in this study. An 
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important future study would be to measure TARS levels in these samples to correlate the 
progression of disease with levels of TARS. We predict that TARS in serum and 
especially ascites fluid will be elevated as the ovarian tumors progress. Together these 
studies suggest an important role for TARS in the angiogenesis and progression of 
ovarian cancer, and TARS should be pursued as a possible future therapeutic target in 
human ovarian cancer. 
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